This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Retain Integer Holdings (ITGR) Stock
by Zacks Equity Research
Integer Holdings (ITGR) continues to gain traction from portfolio management. However, intense competition is a woe.
Integer (ITGR) Up 7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Integer (ITGR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Integer Holdings (ITGR) Stock Now
by Zacks Equity Research
Integer Holdings (ITGR) continues to gain traction from portfolio management. However, intense competition is a woe.
Integer Holdings (ITGR) Gains 2.4% Post Q4 Earnings Beat
by Zacks Equity Research
Integer Holdings' (ITGR) fourth-quarter results reflect weak segmental performance.
Boston Scientific's (BSX) DBS System Gets FDA's Clearance
by Zacks Equity Research
The latest FDA approval of Boston Scientific's (BSX) fourth-generation Vercise Genus DBS System is aimed at improving patients' quality of life.
Here's Why You Should Retain Integer Holdings (ITGR) Stock Now
by Zacks Equity Research
Integer Holdings (ITGR) continues to gain traction from portfolio management. However, intense competition is a woe.
Here's Why You Should Avoid Betting on Integer Holdings (ITGR)
by Zacks Equity Research
Stiff competition in the MedTech space and weak segmental and operational third-quarter 2020 performance weighs on Integer Holdings (ITGR).
Integer Holdings (ITGR) Q3 Earnings Beat Estimates, Down Y/Y
by Zacks Equity Research
Integer Holdings' (ITGR) third-quarter results reflect weak segmental performance.
Integer (ITGR) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Integer (ITGR) delivered earnings and revenue surprises of 56.25% and 2.72%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Integer (ITGR) Q3 Earnings Expected to Decline
by Zacks Equity Research
Integer (ITGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Avoid Betting on Integer Holdings Now
by Zacks Equity Research
Stiff competition in the MedTech space and weak segmental and operational performance weighs on Integer Holdings (ITGR).
Integer (ITGR) Up 2.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Integer (ITGR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Integer Holdings (ITGR) Q2 Earnings Miss Estimates, Down Y/Y
by Zacks Equity Research
Integer Holdings' (ITGR) second-quarter results reflect from weak segmental performance and margin contraction.
Integer (ITGR) Q2 Earnings Miss Estimates
by Zacks Equity Research
Integer (ITGR) delivered earnings and revenue surprises of -20.00% and 1.87%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Integer (ITGR) Q2 Earnings Expected to Decline
by Zacks Equity Research
Integer (ITGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain Integer Holdings Stock for Now
by Zacks Equity Research
Integer Holdings (ITGR) continues to gain traction from solid presence in the broader MedTech space and portfolio management.
Why Is Integer (ITGR) Up 9.8% Since Last Earnings Report?
by Zacks Equity Research
Integer (ITGR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Integer Holdings (ITGR) Q1 Earnings & Revenues Top Estimates
by Zacks Equity Research
Integer Holdings' (ITGR) first-quarter results benefit from strength in Cardio & Vascular sub-segment and margin expansion.
Integer (ITGR) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Integer (ITGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com featured highlights include: Gibraltar Industries, CBIZ, Integer, BioSpecifics Technologies and DHT
by Zacks Equity Research
Zacks.com featured highlights include: Gibraltar Industries, CBIZ, Integer, BioSpecifics Technologies and DHT
Check These 7 Top-Ranked Stocks With Solid Net Profit Margins
by Anirudha Bhagat
Let's take a look at the seven top-ranked stocks with impressive net profit margins for a winning portfolio.
The Zacks Analyst Blog Highlights: InMode, Integer, Cardinal Health, DaVita and The Ensign Group
by Zacks Equity Research
The Zacks Analyst Blog Highlights: InMode, Integer, Cardinal Health, DaVita and The Ensign Group
5 Stocks to Buy for 5 Good Reasons
by Sejuti Banerjea
Here are 5 ways to make the most of a difficult market.
Here's Why You Should Add Integer Holdings to Your Portfolio
by Zacks Equity Research
Integer Holdings (ITGR) continues to gain traction from solid presence in the broader MedTech space and portfolio management.
Find Strong Stocks During the Coronavirus Crisis with this Filtered Zacks Rank 5 Screener
by Benjamin Rains
Today we are going to utilize our Filtered Zacks Rank 5 Screener to help investors find what could be solid investments when stocks start to recover...